ArticleTherapeutic advances in gastroenterology2020
Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis.
Article in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy and safety of multiple treatments for small hepatocellular carcinoma: an updated systematic review and component network meta analysis.EClinicalMedicine · 2026Article
- Article
- A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy.Communications biology · 2026Article
- Postoperative Adjuvant Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma: Patient Selection and Clinical Predictors of Therapeutic Benefit.Journal of hepatocellular carcinoma · 2026Review
- Transcatheter Arterial Chemoembolization May Be Selectively Indicated as Postoperative Adjuvant Therapy for Hepatocellular Carcinoma Patients with Microvascular Invasion.Journal of hepatocellular carcinoma · 2025Article
- Prognostic analysis of different postoperative adjuvant therapies for patients with hepatocellular carcinoma after radical resection with high-risk recurrence factors: a multicenter real-world retrospective study.Frontiers in immunology · 2025Article
- Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.BMC cancer · 2024Article
- Surgical management for hepatocellular carcinoma with concurrent portal vein tumour thrombus and bile duct tumour thrombus: a case report.Annals of medicine and surgery (2012) · 2024Article
- Impact of Hepatic Pedicle Clamping on Long-Term Survival Following Hepatectomy for Hepatocellular Carcinoma: Stratified Analysis Based on Intraoperative Blood Transfusion Status.Annals of surgical oncology · 2024Article
- Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma.Combinatorial chemistry & high throughput screening · 2024Article
- Review
- Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma.eGastroenterology · 2023Article
- Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort.United European gastroenterology journal · 2023Article
- Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy.Frontiers in oncology · 2023Article
- Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.Journal of clinical and translational hepatology · 2022Review
- Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma.International journal of biological sciences · 2022Article
- CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma After Surgical Resection.Journal of hepatocellular carcinoma · 2022Article
- Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.Journal of hematology & oncology · 2021Article
- Review
- Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough adjuvant transcatheter arterial chemoembolization (TACE) has been used to prevent recurrence after surgery in patients with hepatocellular carcinoma (HCC), the survival benefits from adjuvant TACE remain controversial. We sought to systematically evaluate the data on the effectiveness of adjuvant TACE for HCC, as well as identify patient populations that might benefit from adjuvant TACE.
methodsThe PubMed, Embase, Medline and Cochrane library were systematically searched for studies published before July 2019 that compared adjuvant TACE
resultsTwenty-four studies with 6977 patients were included in the analytic cohort. The pooled analysis demonstrated that adjuvant TACE was associated with a better OS and DFS [hazard ratio (HR): 0.67 and 0.67, both
conclusionPostoperative adjuvant TACE may be effective to improve OS and DFS in patients with multinodular HCC, or HCC with MVI or PVTT. Future randomized controlled trials are needed to better define the benefit of adjuvant TACE in subset patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.